Literature DB >> 9678146

A review of famciclovir in the management of genital herpes.

S Faro1.   

Abstract

The frequent occurrence of genital herpes continues to be a serious clinical problem. Although not life threatening, the physical symptoms of the disease, and the ensuing psychosocial complications, can be overwhelming to patients. The life cycle of the herpes simplex virus is complex, comprising multiple stages. Following infection, the virus establishes life-long latency in its host and can reactivate at any time as a recurrent infection. Successful management of genital herpes simplex infections involves patient education and psychological support, as well as antiviral agents. The antiviral agent famciclovir has been shown to shorten the course and decrease the severity of episodes of recurrent genital herpes. In addition, famciclovir has been shown to be effective in suppressing recurrent genital herpes. A review of the clinical experience with famciclovir in the treatment of genital herpes is presented.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678146      PMCID: PMC1784770          DOI: 10.1002/(SICI)1098-0997(1998)6:1<38::AID-IDOG8>3.0.CO;2-3

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  20 in total

1.  Herpes simplex virus type 2 in the United States, 1976 to 1994.

Authors:  D T Fleming; G M McQuillan; R E Johnson; A J Nahmias; S O Aral; F K Lee; M E St Louis
Journal:  N Engl J Med       Date:  1997-10-16       Impact factor: 91.245

Review 2.  NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention.

Authors:  S E Straus; J F Rooney; J L Sever; M Seidlin; S Nusinoff-Lehrman; K Cremer
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

3.  Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group.

Authors:  G J Mertz; M O Loveless; M J Levin; S J Kraus; S L Fowler; D Goade; S K Tyring
Journal:  Arch Intern Med       Date:  1997-02-10

4.  Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.

Authors:  S L Sacks; F Y Aoki; F Diaz-Mitoma; J Sellors; S D Shafran
Journal:  JAMA       Date:  1996-07-03       Impact factor: 56.272

5.  Use of isotopically chiral [4'-13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract.

Authors:  R A Vere Hodge; S J Darlison; S A Readshaw
Journal:  Chirality       Date:  1993       Impact factor: 2.437

6.  Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.

Authors:  S Weller; M R Blum; M Doucette; T Burnette; D M Cederberg; P de Miranda; M L Smiley
Journal:  Clin Pharmacol Ther       Date:  1993-12       Impact factor: 6.875

7.  Recurrence rates in genital herpes after symptomatic first-episode infection.

Authors:  J Benedetti; L Corey; R Ashley
Journal:  Ann Intern Med       Date:  1994-12-01       Impact factor: 25.391

8.  Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency.

Authors:  A M Thackray; H J Field
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

Review 9.  Genital herpes simplex virus infections: clinical manifestations, course, and complications.

Authors:  L Corey; H G Adams; Z A Brown; K K Holmes
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

10.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

View more
  1 in total

Review 1.  Antiviral drugs for viruses other than human immunodeficiency virus.

Authors:  Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.